Related Experiment Video

Updated: Feb 16, 2026

Porcine Model of Infrarenal Abdominal Aortic Aneurysm
11:13

Porcine Model of Infrarenal Abdominal Aortic Aneurysm

Published on: November 21, 2019

9.9K

Fenofibrate and Telmisartan in the Management of Abdominal Aortic Aneurysm

Sophie E Rowbotham1, Smriti M Krishna2, Corey S Moran2

  • 1The University of Queensland; School of Medicine, Herston QLD 4006, Australia; and Department of Vascular Surgery, The Royal Brisbane and Women's Hospital, Herston QLD 4029, Australia.

Current Drug Targets
|December 30, 2017
PubMed
Abstract

Insights

Fenofibrate and telmisartan show promise in limiting abdominal aortic aneurysm (AAA) growth. Ongoing trials are evaluating these repurposed drugs for their potential to slow AAA progression.

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Vascular Biology

Background:

  • Abdominal aortic aneurysm (AAA) growth requires effective drug therapies.
  • Fenofibrate and telmisartan demonstrate potential in preclinical and human studies to impede aortic destruction.
  • These drugs target key inflammatory and molecular pathways implicated in AAA pathogenesis.

Purpose of the Study:

  • To review the rationale and progress of ongoing randomized controlled trials.
  • To assess the efficacy of fenofibrate and telmisartan in limiting abdominal aortic aneurysm growth.
  • To explore the potential of repurposed medications for AAA treatment.

Main Methods:

  • Review of preclinical and human studies on fenofibrate and telmisartan.
  • Analysis of mechanisms of action, including osteopontin reduction and inflammatory pathway modulation.
  • Identification of ongoing randomized controlled trials evaluating these agents in AAA patients.

Main Results:

  • Fenofibrate reduces osteopontin and macrophage recruitment in the aortic wall.
  • Telmisartan blocks angiotensin II receptor type 1 and activates PPARγ, inhibiting AAA biomarkers.
  • Multiple biomarkers including TGF-β1, OPG, osteopontin, and MMP-9 are affected by telmisartan.

Conclusions:

  • Fenofibrate and telmisartan are potential repurposed medications for limiting AAA growth.
  • Randomized trials are currently underway to further evaluate their efficacy in AAA patients.
  • These agents offer a promising avenue for pharmacological intervention in AAA management.
Keywords:
Abdominal aortic aneurysmangiotensinclinical trialfenofibrateosteopontintelmisartan.

More Related Videos

A Calcium Phosphate-Induced Mouse Abdominal Aortic Aneurysm Model05:14

A Calcium Phosphate-Induced Mouse Abdominal Aortic Aneurysm Model

Published on: November 18, 2022

4.5K
Creation of Murine Experimental Abdominal Aortic Aneurysms with Elastase10:23

Creation of Murine Experimental Abdominal Aortic Aneurysms with Elastase

Published on: July 23, 2009

25.3K

Related Concept Videos

Aneurysm IV: Nursing Management01:22

Aneurysm IV: Nursing Management

Vigilant monitoring for aneurysm rupture is essential for patients undergoing aortic surgery.Preoperative Nursing ManagementContinuously monitor the patient for manifestations of aneurysm rupture, such as pallor, weakness, tachycardia, hypotension, abdominal, back, groin, or periumbilical pain, changes in consciousness, and a pulsating abdominal mass. Regularly assess the patient's peripheral pulses.Instruct the patient to consume a clear liquid diet the day before surgery and administer...
488
Aortic Regurgitation IV: Nursing Management01:17

Aortic Regurgitation IV: Nursing Management

A nurse managing a patient with aortic regurgitation begins with a comprehensive assessment, including a review of the patient's medical history, family history, and lifestyle factors. During the cardiac examination, the nurse listens for heart sounds and checks for signs of valve abnormalities. The nurse also observes for symptoms such as dyspnea, orthopnea, and paroxysmal nocturnal dyspnea and assesses the patient's endurance and daily activity tolerance.Based on the findings, the nurse...
330
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
476
Abdominal Aorta01:25

Abdominal Aorta

Once the aorta traverses the diaphragmatic plane at the aortic hiatus, it is known as the abdominal aorta. This anatomical structure is positioned leftward of the spinal column, encased within a cocoon of adipose tissue behind the peritoneal cavity. It terminates at the L4 vertebra, where it splits into the common iliac arteries. Prior to this bifurcation, the abdominal aorta gives rise to several vital branches.
The celiac trunk, a singular artery, divides into the left gastric artery, which...
2.6K
Aneurysm I: Introduction01:30

Aneurysm I: Introduction

An aortic aneurysm is a localized outpouching or dilation at a weak point in the artery wall. It may involve different parts of the aorta, such as the abdominal aorta, aortic arch, or thoracic aorta.Etiological factorsSeveral disorders are associated with aortic aneurysms.Congenital causes, such as primary connective tissue disorders like Marfan syndrome, impact the integrity and strength of connective tissues, notably affecting the aorta. Marfan syndrome is a genetic disorder that specifically...
444
Ultrasound I: Abdominal Ultrasonography01:20

Ultrasound I: Abdominal Ultrasonography

Introduction:
Abdominal ultrasonography, commonly known as abdominal ultrasound, is a vital, non-invasive medical imaging technique widely used in healthcare.
Procedure:
This diagnostic tool allows the clinician to visually inspect internal structures within the abdomen, including vital organs such as the liver, gallbladder, pancreas, kidneys, and spleen.
The abdominal ultrasound process begins with applying a special gel to the patient's skin over the abdomen. This gel enhances the...
1.9K